Meeting
2014 ASCO Annual Meeting
Randomized phase II trial comparing docetaxel with or without low-dose metronomic oral cyclophosphamide in first-line treatment of non-triple-negative advanced breast cancer.
Authors
Leiping Wang
Fudan University Shanghai Cancer Center, Shanghai, China
Leiping Wang , Jian Zhang , Zhong Hua Wang , Biyun Wang , Jun Cao , Fangfang Lv , Sheng Zhang , Shao Zhimin , Xi-Chun Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT01526499
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1041)
DOI
10.1200/jco.2014.32.15_suppl.1041
Abstract #
1041
Poster Bd #
134
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study.
First Author: Takashi Ishikawa
Poster
2011 Breast Cancer Symposium
Effect of oral cyclophosphamide use on pathologic complete response rate in the neoadjuvant treatment of breast cancer.
First Author: M. Luque
Poster
2023 ASCO Annual Meeting
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
First Author: Kay T Yeung
Poster
2023 ASCO Annual Meeting
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
First Author: Rebecca Arielle Shatsky